Early intervention in psychosis: Keeping the body in mind

British Journal of General Practice

Volumn 59, Issue 563, 2009, Pages 395-396

  Shiers, David ^a   Jones, Peter B ^b   Field, Steve ^c,d  

^a National Mental Health Development Unit   (United Kingdom)

^b Cambridgeshire and Peterborough Foundation NHS Trust (CPFT)   (United Kingdom)

^c Bellevue Medical Centre   (United States)

^d RCGP   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE;

BIPOLAR DISORDER; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL FEATURE; EARLY INTERVENTION; EDITORIAL; GENERAL PRACTICE; GENERAL PRACTITIONER; HIGH RISK POPULATION; HUMAN; MEDICAL SPECIALIST; MENTAL HEALTH CARE; METABOLIC DISORDER; MORBIDITY; PATIENT COMPLIANCE; PATIENT REFERRAL; PSYCHOSIS; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; TOBACCO; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ATTITUDE OF HEALTH PERSONNEL; EARLY DIAGNOSIS; FAMILY PRACTICE; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS; YOUNG ADULT;

EID: 67649580551     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp09X420888     Document Type: Editorial

References (24)

1. Kirkbride JB, Fearon P, Morgan C, et al. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study. Arch Gen Psychiatry 2006; 63(3): 250-258. (Pubitemid 43345348)
2. Craig T, Garety P, Power P, et al. The Lambeth Early Onset (LEO) team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ 2004; 329: 1067-1070. (Pubitemid 39490685)
3. Nordentoft M, Jeppesen P, Kassow P, et al. OPUS project: a randomized controlled trial of integrated psychiatric treatment in first episode psychosis - clinical outcome improved. Schizophr Res 2002; 53(Suppl 1): 51.
4. Lester H, Birchwood M, Freemantle N, et al. REDIRECT: cluster randomised controlled trial of GP training in first-episode psychosis. Br J Gen Pract 2009; 59: 403-408.
5. Parks J, Svendsen D, Singer P, Foti ME (eds). Morbidity and mortality in people with serious mental illness. Alexandria, Virginia: National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council, 2006.
6. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatr 1997; 171: 502-508. (Pubitemid 27527317)
7. Disability Rights Commission. Equal treatment: closing the gap. A formal investigation into physical health inequalities experienced by people with learning disabilities and/or mental health problems. London: DRC, 2005.
8. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64(10): 1123-1131. (Pubitemid 47529346)
9. Heiskanen T, Niskanen L, Lyytikäinen R, et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003; 64(5): 575-579. (Pubitemid 36618288)
10. McCreadie R, MacDonald E, Blacklock C, et al. Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study. BMJ 1998; 317(7161): 784-785. (Pubitemid 28427229)
11. Fergusson DM, Poulton R, Smith PF, Boden JM. Cannabis and psychosis. BMJ 2006; 332(7534): 172-175. (Pubitemid 43139414)
12. Office of Deputy Prime Minister. Mental health and social exclusion: Social Exclusion Unit report. London: Office of Deputy Prime Minister, 2004; 11-12.
13. Coulthard M, Farrell M, Singleton N, Meltzer H. Tobacco, alcohol and drug use and mental health. London: Stationery Office, 2002.
14. Wade D, Harrigan S, Edwards J, et al. Course of substance misuse and daily tobacco use in first-episode psychosis. Schizophrenia Res 2006; 81(2-3): 145-150. (Pubitemid 43107688)
15. Willi C, Bodenmann P, Ghali WA et al. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007; 298(22): 2654-2664. (Pubitemid 350254957)
16. Tyrer P, Kendall T. The spurious advance of antipsychotic drug therapy. Lancet 2009; 373(9657): 4-5.
17. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19(Suppl 1): 1-93. (Pubitemid 40677047)
18. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatr 2003; 160(2): 284-289. (Pubitemid 41110453)
19. Tarrant CJ. Blood glucose testing for adults prescribed atypical antipsychotics in primary and secondary care. Psychiatric Bulletin 2006; 30(8): 286-288. (Pubitemid 44236938)
20. Frayne SM, Halanych JH, Miller DR et al. Disparities in diabetes care: impact of mental illness. Arch Intern Med 2005; 165(22): 2631-2638. (Pubitemid 41785061)
21. Kendrick T. Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness. Br J Psychiatry 1996; 169(6): 733-739. (Pubitemid 126735832)
22. National Institute for Health and Clinical Excellence. CG 82 Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update). Clinical Guideline. London: NICE, 2009.
23. Bradshaw T, Lovell K, Harris N. Healthy living interventions and schizophrenia: a systematic review. J Adv Nurs 2005; 49(6): 634-654. (Pubitemid 40417366)
24. Lester H, Tritter JQ, Sorohan H. Patients' and health professionals' views on primary care for people with serious mental illness: focus group study. BMJ 2005; 330(7500): 1122. (Pubitemid 40686196)